Cryoablation was performed using contemporary technology (TRUS [transrectal ultrasound] guidance with argon/helium third-generation equipment), and the study protocol allowed the procedure to be ...

Oncorad Group, an organization specialized in cancer prevention and treatment in Morocco, celebrated the success of the very ...

(ICCM) (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Conclusion: Only cryoablation met the requirement to proceed to a phase 3 study, with an efficacy rate of 94%, a complication rate of 0%, and a 100% treatment tolerance. 94% of patients were very ...

Adagio’s vCLAS TM Cryoablation System, which is currently the subject of an Investigational Device Exemption ("IDE") study called FULCRUM-VT, is a purpose-built system using the Company’s ...

41 women were enrolled in the study, which compared cryoablation to radiofrequency ablation and microwave ablation. Oral presentation and Q&A by Professor Thomas J. Vogl of Germany, titled ...

(Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has received Breakthrough Device ...